MedPath

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Phase 2
Active, not recruiting
Conditions
Melanoma
Interventions
Registration Number
NCT03470922
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab by itself in treating unresectable melanoma or melanoma that has spread.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
714
Inclusion Criteria
  • Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging system
  • Participants must not have had prior systemic anticancer therapy for unresectable or metastatic melanoma
  • Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses
Exclusion Criteria
  • Participants must not have active brain metastases or leptomeningeal metastases
  • Participants must not have uveal melanoma
  • Participants must not have an active, known, or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm A: Relatlimab + NivolumabNivolumabCombination
Arm A: Relatlimab + NivolumabRelatlimabCombination
Arm B: NivolumabNivolumabMonotherapy
Primary Outcome Measures
NameTimeMethod
Progression Free Survival (PFS)From randomization to date of first documented tumor progression or death (up to approximately 33 months)

Progression Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented tumor progression, assessed by a blinded independent central review (BICR) (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who die without a reported progression will be considered to have progressed on the date of their death.

Secondary Outcome Measures
NameTimeMethod
Overall Response Rate (ORR)From randomization up to approximately 3 years

Objective response rate (ORR) is defined as the number of randomized subjects who achieve a best response of complete response (CR) or partial response (PR) based on BICR assessments (using RECIST v1.1 criteria).

Overall Survival (OS)From randomization to the date of death (up to approximately 3 years)

Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause. For subjects that are alive, their survival time will be censored at the date of last contact ("last known alive date").

Trial Locations

Locations (127)

Local Institution - 0124

🇨🇦

Halifax, Nova Scotia, Canada

Local Institution - 0068

🇨🇦

Ottawa, Ontario, Canada

Local Institution - 0128

🇨🇦

Toronto, Ontario, Canada

Local Institution - 0123

🇨🇦

Montreal, Quebec, Canada

Local Institution - 0075

🇨🇦

Montreal, Quebec, Canada

Local Institution - 0001

🇨🇱

Santiago, Metropolitana, Chile

Local Institution - 0095

🇨🇴

Bogota, Colombia

Local Institution - 0127

🇷🇺

Krasnoyarsk, Russian Federation

Local Institution - 0112

🇷🇺

Moscow, Russian Federation

Local Institution - 0023

🇪🇸

A Coruña, Spain

Local Institution - 0024

🇪🇸

Barcelona, Spain

Local Institution - 0025

🇪🇸

Barcelona, Spain

Local Institution - 0026

🇪🇸

Madrid, Spain

Local Institution - 0021

🇪🇸

San Sabastian Gipuzkoa, Spain

Local Institution - 0022

🇪🇸

Sevilla, Spain

Local Institution - 0098

🇸🇪

Goteborg, Sweden

Local Institution - 0099

🇸🇪

Lund, Sweden

Local Institution - 0118

🇸🇪

Solna, Sweden

Local Institution - 0122

🇸🇪

Uppsala, Sweden

Local Institution - 0015

🇺🇸

Ann Arbor, Michigan, United States

Local Institution - 0059

🇧🇷

Rio De Janiro, Brazil

Local Institution - 0060

🇧🇷

Sao Paulo, Brazil

Local Institution - 0062

🇧🇷

Sao Paulo, Brazil

Local Institution - 0082

🇫🇷

Poitiers, France

Local Institution - 0010

🇺🇸

Tucson, Arizona, United States

Local Institution - 0020

🇺🇸

Los Angeles, California, United States

Coastal Integrative Cancer Care

🇺🇸

San Luis Obispo, California, United States

Local Institution - 0116

🇺🇸

Santa Barbara, California, United States

Local Institution - 0012

🇺🇸

Washington, District of Columbia, United States

Local Institution - 0013

🇺🇸

Jacksonville, Florida, United States

Local Institution - 0117

🇺🇸

Orlando, Florida, United States

Local Institution - 0007

🇺🇸

Tampa, Florida, United States

Local Institution - 0038

🇺🇸

Atlanta, Georgia, United States

Local Institution - 0016

🇺🇸

Chicago, Illinois, United States

Local Institution - 0114

🇺🇸

Fort Wayne, Indiana, United States

Local Institution - 0077

🇺🇸

Baltimore, Maryland, United States

Local Institution - 0120

🇺🇸

Baltimore, Maryland, United States

Local Institution - 0014

🇺🇸

Boston, Massachusetts, United States

Local Institution - 0134

🇺🇸

Boston, Massachusetts, United States

Local Institution - 0009

🇺🇸

Minneapolis, Minnesota, United States

Local Institution - 0011

🇺🇸

Rochester, Minnesota, United States

Local Institution - 0018

🇺🇸

Charlotte, North Carolina, United States

Local Institution - 0019

🇺🇸

Allentown, Pennsylvania, United States

Local Institution - 0076

🇺🇸

Dallas, Texas, United States

Local Institution - 0008

🇺🇸

Houston, Texas, United States

Local Institution - 0135

🇦🇷

Buenos Aires, Distrito Federal, Argentina

Local Institution - 0002

🇦🇷

Capital Federal, Distrito Federal, Argentina

Local Institution - 0004

🇦🇷

Buenos Aires, Argentina

Local Institution - 0005

🇦🇷

Buenos Aires, Argentina

Local Institution - 0003

🇦🇷

Ciudad Autónoma De Buenos Aires, Argentina

Local Institution - 0042

🇦🇺

North Sydney, New South Wales, Australia

Local Institution - 0043

🇦🇺

Waratah, New South Wales, Australia

Local Institution - 0041

🇦🇺

Greenslopes, Queensland, Australia

Local Institution - 0045

🇦🇺

Southport, Queensland, Australia

Local Institution - 0133

🇦🇺

Bedford Park, South Australia, Australia

Local Institution - 0044

🇦🇺

Murdoch, Western Australia, Australia

Local Institution - 0036

🇦🇹

Graz, Steiermark, Austria

Local Institution - 0037

🇦🇹

Salzburg, Austria

Local Institution - 0035

🇦🇹

Wien, Austria

Local Institution - 0047

🇧🇪

Brussels, Belgium

Local Institution - 0049

🇧🇪

Bruxelles, Belgium

Local Institution - 0048

🇧🇪

Gent, Belgium

Local Institution - 0058

🇧🇷

Belo Horizonte, Minas Gerais, Brazil

Local Institution - 0057

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Local Institution - 0061

🇧🇷

Porto Alegre, RIO Grande DO SUL, Brazil

Local Institution - 0073

🇧🇷

Santa Cruz do Sul, RIO Grande DO SUL, Brazil

Local Institution - 0063

🇧🇷

São Paulo, SAO Paulo, Brazil

Local Institution - 0096

🇨🇴

Medellín, Antioquia, Colombia

Local Institution - 0105

🇩🇰

Aarhus N, Midtjylland, Denmark

Local Institution - 0103

🇩🇰

Herlev, Denmark

Local Institution - 0104

🇩🇰

Odense, Denmark

Local Institution - 0100

🇫🇮

Helsinki, Uusimaa, Finland

Local Institution - 0102

🇫🇮

Oulu, Finland

Local Institution - 0119

🇫🇮

Tampere, Finland

Local Institution - 0101

🇫🇮

Turku, Finland

Local Institution - 0080

🇫🇷

Bordeaux Cedex, France

Local Institution - 0085

🇫🇷

Lille, France

Local Institution - 0081

🇫🇷

Marseille, France

Local Institution - 0131

🇩🇪

Tübingen, Baden-Württemberg, Germany

Local Institution - 0071

🇩🇪

Quedlinburg, Sachsen-Anhalt, Germany

Local Institution - 0032

🇩🇪

Buxtehude, Germany

Local Institution - 0030

🇩🇪

Erfurt, Germany

Local Institution - 0027

🇩🇪

Essen, Germany

Local Institution - 0033

🇩🇪

Hannover, Germany

Local Institution - 0074

🇩🇪

Homburg / Saar, Germany

Local Institution - 0029

🇩🇪

Köln, Germany

Local Institution - 0084

🇫🇷

Rennes, Ille-et-Vilaine, France

Local Institution - 0079

🇫🇷

Amiens, Somme, France

Local Institution - 0083

🇫🇷

Paris, France

Local Institution - 0078

🇫🇷

Pierre-Benite, France

Local Institution - 0132

🇩🇪

Heidelberg, Baden-Württemberg, Germany

Local Institution - 0028

🇩🇪

Lubeck, Germany

Local Institution - 0072

🇩🇪

Mannheim, Germany

Local Institution - 0034

🇩🇪

Muenchen, Germany

Local Institution - 0031

🇩🇪

Wuerzburg, Germany

Local Institution - 0064

🇬🇷

Athens, Greece

Local Institution - 0065

🇬🇷

Thessaloniki, Greece

Local Institution - 0086

🇮🇱

Haifa, Israel

Local Institution - 0088

🇮🇱

Jerusalem, Israel

Local Institution - 0087

🇮🇱

Ramat-gan, Israel

Local Institution - 0111

🇮🇹

Torino, Piemonte, Italy

Local Institution - 0109

🇮🇹

Bergamo, Italy

Local Institution - 0108

🇮🇹

Milano, Italy

Local Institution - 0106

🇮🇹

Napoli, Italy

Local Institution - 0110

🇮🇹

Padova, Italy

Local Institution - 0107

🇮🇹

Siena, Italy

Local Institution - 0094

🇲🇽

Zapopan, Jalisco, Mexico

Local Institution - 0091

🇲🇽

Monterrey, Nuevo LEON, Mexico

Local Institution - 0093

🇲🇽

Cancún, Quintana Roo, Mexico

Local Institution - 0092

🇲🇽

Mérida, Yucatán, Mexico

Local Institution - 0129

🇲🇽

Veracruz, Mexico

Local Institution - 0090

🇳🇿

Dunedin, New Zealand

Local Institution - 0125

🇳🇿

Hamilton, New Zealand

Local Institution - 0089

🇳🇿

Tauranga, New Zealand

Local Institution - 0121

🇳🇴

Oslo, Norway

Local Institution - 0040

🇵🇱

Poznan, Poland

Local Institution - 0039

🇵🇱

Warszawa, Poland

Local Institution - 0070

🇷🇴

Cluj-Napoca, Cluj, Romania

Local Institution - 0066

🇷🇴

Bucharest, Romania

Local Institution - 0067

🇷🇴

Craiova, Romania

Local Institution - 0069

🇷🇴

Iasi, Romania

Local Institution - 0113

🇷🇺

Krasnodar, Russian Federation

Local Institution - 0052

🇬🇧

Bristol, Avon, United Kingdom

Local Institution - 0054

🇬🇧

Glasgow, Dumfries & Galloway, United Kingdom

Local Institution - 0056

🇬🇧

Swansea, Glamorgan, United Kingdom

Local Institution - 0051

🇬🇧

London, Greater London, United Kingdom

Local Institution - 0126

🇬🇧

Inverness, Inverness-shire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath